

| Essential Plan

Drugs That Require Step Therapy (ST)

In some cases, **Mutual of Omaha Rx**SM (PDP) requires you to first try certain drugs to treat your medical condition before we will cover another drug for that condition. For example, if Step 1 and Step 2 drugs both treat your medical condition, we may not cover the Step 2 drug unless you try the Step 1 drug first. If the Step 1 drug does not work for you, we will then cover the Step 2 drug.

You will need authorization from Mutual of Omaha Rx before filling prescriptions for the Step 2 drugs shown in the following charts. Mutual of Omaha Rx will only provide coverage after it determines that the drug is being prescribed according to the criteria specified in the chart.

Express Scripts, a pharmacy benefit manager, administers the review process for Mutual of Omaha Rx. To request a review, please have your physician visit their online portal at **esrx.com/PA**. You, your appointed representative or your prescriber can also request a review by calling Express Scripts toll free at **1.800.935.6103**, 24 hours a day, 7 days a week. Customer Service is available in Englishand other languages. TTY users should call **1.800.716.3231**.

The formulary may change at any time. You will receive notice when necessary.

Express Scripts is the pharmacy benefit manager for Mutual of Omaha Rx and will be providing some services on behalf of Mutual of Omaha Rx.

Mutual of Omaha Rx (PDP) is a prescription drug plan with a Medicare contract. Enrollment in the Mutual of Omaha Rx plan depends on contract renewal.

No changes made since 09/25/2023

BASAL INSULIN - PST

Products Affected

Step 2:

- Basaglar KwikPen U-100 Insulin 100 unit/mL (3 mL) subcutaneous
- Levemir FlexPen 100 unit/mL (3 mL) solution subcutaneous insulin pen

• Levemir U-100 Insulin 100 unit/mL subcutaneous solution

Criteria	If the patient has tried one Step 1 drug, approve the requested Step 2 drug. If the patient is pregnant, approve Levemir without a trial of a Step 1 product. Approve Levemir for patients who are greater than or equal to 2 but less than 6 years old without a trial of a Step 1 product.
----------	--

DEXTROMETHORPHAN/BUPROPION

Products Affected

Step 2:

Auvelity 45 mg-105 mg tablet, extended release

Criteria	Approve if the patient has tried a generic SSRI OR SNRI AND separately	
	tried bupropion. Approve Auvelity if the patient has suicidal ideation without a trial of a Step 1 drug. Approve Auvelity if the patient is	
	currently receiving Auvelity or has taken Auvelity in the past.	

PULMONARY ANTIINFLAMMATORY - PST

Products Affected

Step 2:

- fluticasone propionate 110 mcg/actuation fluticasone propionate 44 mcg/actuation HFA aerosol inhaler
- fluticasone propionate 220 mcg/actuation HFA aerosol inhaler
- HFA aerosol inhaler

Criteria	If the patient has tried TWO Step 1 drugs, approve the requested Step 2 drug. If the patient is 4 years of age or younger and has a low inspiratory flow rate and is unable to use a dry powder inhaler, approve fluticasone propionate HFA (AA to Flovent HFA) if the patient has tried Qvar RediHaler.
----------	--

RAPID-ACTING INSULIN - PST

Products Affected

Step 2:

- Novolog FlexPen U-100 Insulin aspart 100 unit/mL (3 mL) subcutaneous
- Novolog Mix 70-30 FlexPen U-100 Insulin 100 unit/mL subcutaneous pen
- NOVOLOG PENFILL U-100 INSULIN ASPART 100 UNIT/ML SUBCUTANEOUS CARTRIDGE

Index

A	${f L}$
Auvelity 45 mg-105 mg tablet, extended	Levemir FlexPen 100 unit/mL (3 mL)
release2	solution subcutaneous insulin pen 1
В	Levemir U-100 Insulin 100 unit/mL
Basaglar KwikPen U-100 Insulin 100	subcutaneous solution1
unit/mL (3 mL) subcutaneous	N
F	Novolog FlexPen U-100 Insulin aspart 100
fluticasone propionate 110 mcg/actuation	unit/mL (3 mL) subcutaneous4
HFA aerosol inhaler3	Novolog Mix 70-30 FlexPen U-100 Insulin
fluticasone propionate 220 mcg/actuation	100 unit/mL subcutaneous pen 4
HFA aerosol inhaler3	Novolog PenFill U-100 Insulin aspart 100
fluticasone propionate 44 mcg/actuation	unit/mL subcutaneous cartridg 4
HFA aerosol inhaler3	_